# Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

> **NCT05720026** · PHASE3 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 560 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** SYSA1901
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05720026
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-09
- **Primary completion:** 2025-08-29
- **Final completion:** 2026-02-21
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720026, "Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05720026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*